RECIST was developed in 2000 by the National Cancer Institute, European Organization for Research and Treatment of Cancer, and National Cancer Institute of Canada, with revision to RECIST 1.1 in 2009 ...

Recently, extraordinary progress has been made in our understanding of the mechanisms and molecular pathways underlying focal and sclerotic bone diseases, rare disorders which have a strong genetic ...

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).

CT attenuation measurements can be used to distinguish untreated osteoblastic (bone-related) metastases from enostoses (benign bone lesions), a team of researchers has found. A team of Boston ...

Monoclonal gammopathy of undetermined significance is a diagnosis of exclusion, but even once it has been identified, patients should not obsess over this precancerous condition, said Ajai Chari, MD, ...